Two Seas Capital LP Purchases 1,324,022 Shares of uniQure N.V. $QURE

by · The Cerbat Gem

Two Seas Capital LP purchased a new position in shares of uniQure N.V. (NASDAQ:QURE – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 1,324,022 shares of the biotechnology company’s stock, valued at approximately $31,988,000. uniQure makes up about 0.4% of Two Seas Capital LP’s holdings, making the stock its 23rd largest position. Two Seas Capital LP owned about 1.91% of uniQure as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Hennion & Walsh Asset Management Inc. grew its position in uniQure by 107.3% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 142,113 shares of the biotechnology company’s stock valued at $6,546,000 after acquiring an additional 73,566 shares during the last quarter. Royal Bank of Canada lifted its holdings in shares of uniQure by 26.0% in the first quarter. Royal Bank of Canada now owns 107,888 shares of the biotechnology company’s stock worth $1,763,000 after acquiring an additional 22,248 shares during the last quarter. Kalehua Capital Management LLC acquired a new stake in shares of uniQure in the 1st quarter valued at approximately $4,760,000. Voss Capital LP boosted its stake in shares of uniQure by 68.0% in the 4th quarter. Voss Capital LP now owns 210,000 shares of the biotechnology company’s stock valued at $5,025,000 after purchasing an additional 85,000 shares in the last quarter. Finally, Orbimed Advisors LLC boosted its stake in shares of uniQure by 189.7% in the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after purchasing an additional 1,398,749 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company reiterated an “overweight” rating and set a $75.00 price objective on shares of uniQure in a research report on Tuesday, September 29th. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price on the stock in a research note on Wednesday, June 17th. Weiss Ratings upgraded shares of uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 21st. William Blair upgraded uniQure to a “strong-buy” rating in a research note on Wednesday, September 23rd. Finally, Mizuho raised their price objective on uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $53.73.

View Our Latest Stock Analysis on uniQure

uniQure Trading Up 1.1%

NASDAQ:QURE traded up $0.26 during mid-day trading on Tuesday, hitting $23.06. 2,823,008 shares of the company’s stock were exchanged, compared to its average volume of 2,468,617. The company has a 50 day simple moving average of $42.99 and a 200-day simple moving average of $33.50. The company has a current ratio of 10.01, a quick ratio of 10.01 and a debt-to-equity ratio of 0.15. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The firm has a market capitalization of $1.60 billion, a P/E ratio of -5.75 and a beta of 1.06.

uniQure (NASDAQ:QURE – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The business had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same quarter last year, the company posted ($0.69) earnings per share. As a group, research analysts expect that uniQure N.V. will post -3.82 earnings per share for the current year.

uniQure Profile

(Free Report)

uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration.

uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy.

Further Reading